| Literature DB >> 34254289 |
Sameem Abedin1, Nahid Rashid2, Mark Schroeder3, Rizwan Romee4, Mary Nauffal5, Muhamad Alhaj Moustafa6, Mohamed A Kharfan-Dabaja6, Jeanne Palmer7, William Hogan8, Mehrdad Hefazi8, Samantha Larson9, Shernan Holtan10, Zachariah DeFilipp11, Reena Jayani12, Bhagirathbhai Dholaria12, Joseph Pidala13, Farhad Khimani13, Michael R Grunwald14, Candace Butler14, Mehdi Hamadani1.
Abstract
Ruxolitinib for steroid-refractory acute graft-versus-host disease (SR-aGVHD) results in resistance or intolerance in 1/5 of patients. Outcomes of such patients are undefined. We identified these patients in a multicentre review and reported outcomes. Ruxolitinib-resistant aGVHD was identified in 48/307 patients. Among patients receiving additional therapy, the overall response rate to next therapy was 36%. Median survival was 21 days. Ruxolitinib intolerance led to treatment discontinuation in 16/307 patients. Ten intolerant patients received additional therapy with 50% experiencing continued improvement of aGVHD. Median survival was 50 days in these patients. These data serve as a baseline for future SR-aGVHD studies.Entities:
Keywords: graft-versus-host disease; stem cell transplantation; transplant
Mesh：
Substances：
Year: 2021 PMID： 34254289 PMCID： PMC9293486 DOI： 10.1111/bjh.17700
Source DB: PubMed Journal: Br J Haematol ISSN： 0007-1048 Impact factor: 8.615